GENENTECH, INC.

GENENTECH, INC. logo
🇺🇸United States
Ownership
Subsidiary
Established
1976-01-01
Employees
11.1K
Market Cap
-
Website
http://www.gene.com

A Study of PRO95780 in Patients With Advanced Chondrosarcoma (APM4171g)

Phase 2
Terminated
Conditions
Interventions
First Posted Date
2007-10-15
Last Posted Date
2022-12-13
Lead Sponsor
Genentech, Inc.
Target Recruit Count
15
Registration Number
NCT00543712
Locations
🇺🇸

Sarcoma Oncology Center, Santa Monica, California, United States

🇦🇺

Peter MacCallum Cancer Centre, Melbourne, Australia

🇺🇸

Dana Farber Cancer Institute, Boston, Massachusetts, United States

and more 1 locations

A Study of rhuMAb IFNalpha in Adults With Systemic Lupus Erythematosus

Phase 1
Completed
Conditions
First Posted Date
2007-10-10
Last Posted Date
2011-09-22
Lead Sponsor
Genentech, Inc.
Target Recruit Count
60
Registration Number
NCT00541749

A Study of PRO95780 in Combination With Rituximab in Patients With Non-Hodgkin's Lymphoma That Has Progressed Following Previous Rituximab Therapy (APM4083g)

Phase 2
Completed
Conditions
Interventions
First Posted Date
2007-08-16
Last Posted Date
2017-06-06
Lead Sponsor
Genentech, Inc.
Target Recruit Count
49
Registration Number
NCT00517049

A Study of Trastuzumab Emtansine (Trastuzumab-MCC-DM1) Administered Intravenously to Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer

First Posted Date
2007-07-31
Last Posted Date
2013-04-02
Lead Sponsor
Genentech, Inc.
Target Recruit Count
112
Registration Number
NCT00509769
Locations
🇺🇸

USO, Dallas, Texas, United States

🇺🇸

Lynn Cancer Institute - West, Boca Raton, Florida, United States

🇺🇸

Florida Cancer Care, Davie, Florida, United States

and more 35 locations

A Trial of the Safety of Escalating Doses of PRO131921 in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

Phase 1
Terminated
Conditions
Interventions
First Posted Date
2007-07-04
Last Posted Date
2017-07-02
Lead Sponsor
Genentech, Inc.
Target Recruit Count
16
Registration Number
NCT00496132

A Study of Omalizumab in Preventing Bronchoconstriction Following Environmental Cat Dander Exposure in Patients With Cat Dander-induced Asthma

Phase 4
Completed
Conditions
Interventions
First Posted Date
2007-07-03
Last Posted Date
2017-06-08
Lead Sponsor
Genentech, Inc.
Target Recruit Count
69
Registration Number
NCT00495612

A Study Evaluating the Efficacy and Safety of Sunitinib With or Without Bevacizumab in First-Line Patients With Metastatic Renal Cell Cancer (SABRE-R)

First Posted Date
2007-06-26
Last Posted Date
2009-04-10
Lead Sponsor
Genentech, Inc.
Target Recruit Count
16
Registration Number
NCT00491738
© Copyright 2024. All Rights Reserved by MedPath